GSK and Empirico Partnership
GSK has signed a licensing deal with Empirico for its respiratory disease-focused silent interfering RNA (siRNA), EMP-012, in a $745m deal.
GSK now owns the global development and commercialisation rights to Empirico's COPD-targeting oligonucleotide, EMP-012, which is currently in Phase I trials for chronic obstructive pulmonary disease (COPD).
- The deal includes an $85m upfront payment.
- Empirico is eligible to claim up to $660m in development, regulatory and commercial milestone payments.
- If EMP-012 reaches the market, Empirico will also receive tiered royalties on net global sales.
The total deal value is $745m.
Author's summary: GSK partners with Empirico in a $745m deal.
More News
- Illinois House Democrats push first-in-the-world wealth tax, streaming, concert taxes
- Mariah The Scientist Honors Young Thug With “Cater 2 U” Performance At Birthday Bash
- Landry's Explosive Quote That Signals Major Changes at LSU
- This ‘impressive’ AI model predicted Hurricane Melissa’s perilous growth
- Missouri Department of Conservation explains importance of managed deer hunts
- While Mel Owens Hunts for Love on TV, His Ex-Wife Already Found It
- What makes a scientific breakthrough truly chemical?
- DAC Companies Pivot on High Costs, Funding Cuts
- The children are starving; God is screaming – Baptist News Global
- Will today’s Fed rate cut be last one until summer 2026? - Sharecafe